52
Participants
Start Date
October 9, 2017
Primary Completion Date
September 17, 2019
Study Completion Date
September 17, 2019
INCAGN01949
In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
Nivolumab
Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
Ipilimumab
Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
New York University Clinical Cancer Center, New York
University of Rochester Medical Center, Rochester
Fox Chase Cancer Center, Philadelphia
Carolina BioOncology Institute, Huntersville
Mount Sinai Medical Center of Florida, Inc., Miami
Sarah Cannon Research Institute, LLC (SCRI), Nashville
Vanderbilt University Medical Center, Nashville
University of Michigan, Ann Arbor
Barbara Ann Karmanos Cancer Institute, Detroit
Scottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale
The University of Alabama Birmingham (UAB), Birmingham
The Angeles Clinic and Research Institute, Los Angeles
Providence Portland Medical Center, Portland
John Theurer Cancer Center At Hackensack UMC, Hackensack
Rutgers, The State University, New Brunswick
Lead Sponsor
Incyte Biosciences International Sàrl
INDUSTRY